The stock of Intellia Therapeutics Inc (NASDAQ: NTLA) has decreased by -4.56% when compared to last closing price of $10.74. Despite this, the company has experienced a 7.22% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-07 that CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on July 1, 2025, it awarded an inducement grant to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
Is It Worth Investing in Intellia Therapeutics Inc (NASDAQ: NTLA) Right Now?
The 36-month beta value for NTLA is at 2.30. Analysts have varying views on the stock, with 18 analysts rating it as a “buy”, 4 rating it as “overweight”, 6 as “hold”, and 0 as “sell”.
The public float for NTLA is 97.42M, and currently, shorts hold a 30.48% of that float. The average trading volume for NTLA on July 08, 2025 was 4.47M shares.
NTLA’s Market Performance
NTLA’s stock has seen a 7.22% increase for the week, with a 33.64% rise in the past month and a 48.77% gain in the past quarter. The volatility ratio for the week is 7.80%, and the volatility levels for the past 30 days are at 7.51% for Intellia Therapeutics Inc The simple moving average for the last 20 days is 10.38% for NTLA stock, with a simple moving average of -13.55% for the last 200 days.
Analysts’ Opinion of NTLA
Many brokerage firms have already submitted their reports for NTLA stocks, with Wolfe Research repeating the rating for NTLA by listing it as a “Outperform”. The predicted price for NTLA in the upcoming period, according to Wolfe Research is $21 based on the research report published on April 21, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NTLA reach a price target of $30. The rating they have provided for NTLA stocks is “Buy” according to the report published on March 05th, 2025.
Goldman gave a rating of “Sell” to NTLA, setting the target price at $9 in the report published on February 28th of the current year.
NTLA Trading at 17.57% from the 50-Day Moving Average
After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.63% of loss for the given period.
Volatility was left at 7.51%, however, over the last 30 days, the volatility rate increased by 7.80%, as shares surge +35.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.70% upper at present.
During the last 5 trading sessions, NTLA rose by +7.22%, which changed the moving average for the period of 200-days by -52.35% in comparison to the 20-day moving average, which settled at $9.29. In addition, Intellia Therapeutics Inc saw -53.72% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NTLA starting from Clark Eliana, who sold 1,022 shares at the price of $9.82 back on Jul 01 ’25. After this action, Clark Eliana now owns 95,369 shares of Intellia Therapeutics Inc, valued at $10,036 using the latest closing price.
Dube Michael P, the VP, Chief Accounting Officer of Intellia Therapeutics Inc, sale 2,503 shares at $9.95 during a trade that took place back on Jul 02 ’25, which means that Dube Michael P is holding 57,137 shares at $24,905 based on the most recent closing price.
Stock Fundamentals for NTLA
Current profitability levels for the company are sitting at:
- -11.87% for the present operating margin
- 0.89% for the gross margin
The net margin for Intellia Therapeutics Inc stands at -11.54%. The total capital return value is set at -0.62%. Equity return is now at value -57.92%, with -46.84% for asset returns.
Based on Intellia Therapeutics Inc (NTLA), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -3.16.
Currently, EBITDA for the company is -523.98 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 23.13. The receivables turnover for the company is 4.34for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.
Conclusion
In conclusion, Intellia Therapeutics Inc (NTLA) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
